, Volume 24, Issue 1, pp 15-32

Cardiotonic bipyridine amrinone slows myosin-induced actin filament sliding at saturating [MgATP]

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Previously reported effects of amrinone on skeletal muscle function suggest that the drug reduces the rate constant of myosin cross-bridge dissociation. We have used the in vitro motility assay to further elucidate the mechanism underlying this effect and to aid these studies a new, improved, filament tracking software was developed in the Matlab™ environment. The experiments were carried out at 30°C using heavy meromyosin from fast rabbit muscle and rhodamine–phalloidin labeled actin filaments. A slowing effect of amrinone on filament sliding velocity at 1mM MgATP was observed at drug concentrations >0.3 mM. This effect showed signs of saturation at the highest drug concentrations (1–2 mM) that could be readily tested. The sliding velocity exhibited hyperbolic dependence on [MgATP] with a V max of 7.2 ± 0.9 μm/s and a K M of 0.18 ± 0.02 mM. Amrinone (1 mM) reduced V max by 32 ± 5% (P < 0.01) and K M by 42 ± 8% (P < 0.05; n = 4). These results are accounted for in the most straightforward way by a model where amrinone acts directly on the actomyosin system and reduces the rate constant of MgADP release. Such a well-defined effect on the myosin cross-bridge cycle makes the drug a potentially useful pharmacological tool for further studies of myosin function both in vitro and in the ordered filament array of a living muscle fiber.

This revised version was published online in July 2006 with corrections to the Cover Date.